Brief: BioInvent International Gets $3 Mln Capital Equity Investment

BioInvent International AB

18/01/2023 07:40

Jan 18(Reuters) - BioInvent International AB  BINV.ST :
    * SAID ON TUESDAY, HAS BEEN SELECTED AS PARTNER OF THE
LEUKEMIA &
LYMPHOMA SOCIETY'S THERAPY ACCELERATION PROGRAM
    * PARTNERSHIP INCLUDES ACCESS TO SCIENTIFIC, CLINICAL AND
DRUG
DEVELOPMENT EXPERTISE OF LLS, AND $3 MILLION STRATEGIC CAPITAL
EQUITY INVESTMENT FROM LLS TAP
    * STRATEGIC EQUITY INVESTMENT OF $3 MILLION TO SUPPORT
CLINICAL
ADVANCEMENT OF BI-1206 IN NON-HODGKIN’S LYMPHOMA
    * STRATEGIC INVESTMENT ALSO SUPPORTS CLINICAL DEVELOPMENT OF
BI-1808 IN CUTANEOUS T-CELL LYMPHOMA
    * FOLLOWING SHARE ISSUE, LLS TAP WILL OWN ABOUT 1.27 % OF
THE
SHARES IN BIOINVENT

        
 Source text for Eikon:  urn:newsml:reuters.com:*:nMFN1RMPsJ
 Further company coverage:  BINV.ST  
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))